Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033 - Projected to Generate Revenues of $20.63 Billion by 2028, Fueled by Advances in Liquid Biopsy and Personalized Medicine
13 déc. 2024 09h49 HE
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033" report has been added to ResearchAndMarkets.com's offering.The cell free DNA (cfDNA)...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
10 déc. 2024 08h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Nano Drug Delivery System (NDDS) in Cancer Therapy Global Industry Research Report 2024 - Global Forecast to 2030 with Competitive Profiles of 45+ Key Players
03 déc. 2024 10h04 HE
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "NDDS in Cancer Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for NDDS in...
Exosome Diagnostics & Therapeutics Market Assessment 2025-2030 Featuring Strategic Profiles of the Industry's Leading and Emerging Players
28 nov. 2024 06h56 HE
|
Research and Markets
Dublin, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The "Exosome Diagnostics & Therapeutics Market by Product, Application, End User - Global Forecast 2025-2030" report has been added to ...
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
22 nov. 2024 16h30 HE
|
Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Patient Derived Xenograft (PDX) Models Market Expects Significant Growth, Reaching $710 Million by 2028 - Global Long-term Forecasts to 2033
21 nov. 2024 11h30 HE
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Patient Derived Xenograft (PDX) Models Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The patient derived...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
20 nov. 2024 08h30 HE
|
Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...
Precision Medicine Software Market Report 2024-2029: Industry Trends, Business Opportunities, Competitive Intelligence, Regional Growth Forecasts
31 oct. 2024 07h43 HE
|
Research and Markets
Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Precision Medicine Software Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Precision Medicine...
Modifi Biosciences Acquired by Merck
23 oct. 2024 07h05 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...